

In the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims

- 1) (Currently Amended) A method for identifying a binding member capable of occupying a substrate binding site on the CCT complex or part thereof, wherein the binding member inhibits the binding of the CCT substrate to and the CCT complex or part thereof.
- 2) (Previously Amended) A method according to claim 1 wherein the binding member is an antibody.
- 3) (Currently Amended) A method according to claim 1 wherein the binding member is ~~selected from the group consisting of a peptide and a peptide fragment~~.
- 4) (Previously Amended) A method according to claim 3 wherein the binding member is greater than 5 amino acids in length.
- 5) (Previously Amended) A method according to claim 4 wherein the binding member is from 5 to 40 amino acids in length.
- 6) (Previously Amended) A method according to claim 3 wherein the binding member is derived from a CCT substrate.
- 7) (Currently Amended) A method according to claim 6 wherein the substrate from which the binding member is derived is selected from the group consisting of actin, tubulin or cyclin.
- 8) (Currently Amended) A method according to claim 7 wherein the substrate from which the binding member is derived is actin.
- 9) (Currently Amended) A method according to claim 3 wherein the binding member comprises a sequence selected from the group of SEQ ID NOS: 1-15 sequences shown in Figure 10.
- 10) (Previously Amended) A method according to claim 9 wherein the binding member comprises the amino acid sequence GRPRH (SEQ ID NO: 121).
- 11) (Currently Amended) A method of identifying a binding member capable of occupying a substrate binding site on a CCT apical domain; comprising the steps of

contacting a candidate binding member with said CCT apical domain; and

determining binding between said candidate binding member and the CCT apical domain

wherein the binding member inhibits the binding of the CCT substrate to the CCT apical domain.

- 12) (Currently Amended) A method according to claim 11 wherein the binding member is ~~selected from the group consisting of a peptide and a peptide fragment.~~
- 13) (Currently Amended) A method according to claim 12 wherein the candidate binding member is a peptide ~~or peptide fragment~~ having an amino acid sequence corresponding to the amino acid sequence of a CCT ~~apical domain~~ substrate.
- 14) (Original) A method according to claim 13 wherein the CCT substrate is actin.
- 15) (Original) A method according to claim 14 wherein the CCT substrate is tubulin.
- 16) (Currently Amended) A method according to claim 12 wherein the peptide ~~or peptide fragment~~ comprises a sequence selected from the group of sequences shown in Fig-
40 SEQ ID NOS 1 – 15.
- 17) (Previously Amended) A method according to claim 11 further comprising the step of immobilizing the candidate binding member on a solid phase prior to contacting with the CCT apical domain.
- 18) (Previously Amended) A method according to claim 11 further comprising the step of modifying the candidate binding member to improve its binding with the CCT apical domain.
- 19) (Previously Amended) A method according to claim 11 wherein binding between the candidate binding member and the CCT apical domain is determined by a competitive assay.
- 20) (Currently Withdrawn) A binding member capable of occupying a CCT substrate binding site, comprising of an amino acid sequence of 5 to 40 amino acids derived from a CCT substrate.
- 21) (Currently Withdrawn) A binding member according to claim 20 wherein the CCT substrate is selected from the group consisting of actin, tubulin or cyclin.
- 22) (Currently Withdrawn) A binding member according to claim 21 wherein the CCT substrate is actin.
- 23) (Currently Withdrawn) A binding member according to claim 22 comprising any one of the amino acid sequences selected from the group of sequences shown in Fig. 10.
- 24) (Currently Withdrawn) A binding member according to claim 23 comprising the amino acid sequence GRPRH (SEQ ID NO: 121).

- 25) (Currently Withdrawn) A binding member according to claim 20 having binding affinity for a CCT complex such that it blocks a substrate binding site on said CCT complex thereby effecting the biological activity of the CCT complex.
- 26) (Currently Withdrawn) A binding member according to claim 20 linked to a coupling partner.
- 27) (Currently Withdrawn) A binding member according to claim 26 wherein the coupling partner is a second peptide and the binding member and the second peptide form a fusion protein.
- 28) (Currently Withdrawn) A binding member according to claim 20 for use in medical treatment.
- 29) (Currently Withdrawn) A medicament for the treatment of cancer cells, said medicament comprising a binding member as claimed in claim 20, said medicament being administered to said cells to effect the biological activity of a CCT complex within the cell.
- 30) (Currently Withdrawn) A medicament according to claim 29 wherein the medicament further comprises a cancer drug.
- 31) (Currently Amended) A method for screening for mimetics of binding members capable of occupying a CCT substrate binding site, comprising of an amino acid sequence of 5 to 40 amino acids derived from a CCT substrate, wherein said binding member has been identified by a method of claim 1 or claim 11, the method according to claim 20 comprising exposing said binding members and a candidate mimetic to a CCT substrate binding site or active portion thereof, so that the candidate mimetic and the binding member compete to bind to the CCT substrate binding site; and detecting the extent of binding of the candidate mimetic or the binding member to the CCT substrate binding site; wherein a mimetic of the binding members binds to the CCT substrate binding site or reduces the extent of binding of the binding member o the CCT substrate binding site.
- 32) (Currently Amended) A method according to claim 31 further comprising screening the candidate mimetics for ~~biological activity~~ the ability to affect the normal biological activity of CCT in a cell.
- 33) (Original) A method according to claim 32 wherein the biological activity is the inhibition of cytoskeletal assembly.
- 34) (Original) A method according to claim 32 wherein the biological activity is CCT complex dis-assembly.
- 35) (Currently Amended) A method according to claim ~~27~~ 31 wherein the binding member or the candidate mimetic is immobilized on a solid support.

- 36) (Currently Amended) A method according to claim 31 wherein the extent of binding of the candidate mimetic is detected by labelling the CCT substrate binding site complex or part thereof having a substrate binding site ~~active portion thereof~~ or by using a labelled antibody capable of binding to the CCT substrate binding domain.
- 37) (Previously Amended) A method according to claim 36 wherein the CCT substrate binding site comprises the sequence corresponding to residues D219 to N394 of CCT δ .
- 38) (Currently Withdrawn) A pharmaceutical composition comprising a binding member according to claim 20 in combination with a pharmaceutically acceptable carrier.
- 39) (Currently Withdrawn) A CCT apical domain having at least 80% homology with the amino acid sequence of D219 to N394 of CCT δ .
- 40) (Currently Withdrawn) A nucleic acid molecule encoding the polypeptide according to claim 39.
- 41) (Currently Withdrawn) A vector comprising the nucleic acid according to claim 40.
- 42) (Currently Withdrawn) A host cell comprising the vector according to claim 41.
- 43) (Currently Withdrawn) A host cell comprising the nucleic acid according to claim 40.